A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001).
Patients with a locally advanced or metastatic RET Fusion-Positive solid tumors
To assess, for each phase 2 expansion cohort, the anti-tumor activity of LOXO-292 by determining ORR using RECIST 1.1 or RANO, as appropriate to tumor type, as assessed by independent review committee (IRC).
In- and exclusion Criteria
Prior MKIs with anti-RET activity are allowed. Refer to Appendix A for examples of MKIs with anti-RET activity. However, prior treatment with a selective RET inhibitor(s) (including investigational selective RET inhibitor[s]) is prohibited
Inc. 281 Tresser Boulevard, 9th Floor
Stamford, CT 06901
Klinik I für Innere Medizin/LCGC
Telefon: +49 221 478 87008
Fax: +49 221 478 87010
Prof. J. Wolf
Last Update: 23. August 2019